ClinicalTrials.gg
CompletedNCT00574379Updated Feb 15, 2019

Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR

A Phase 2 interventional study of Bilastine and Placebo in Seasonal Allergic Rhinitis, Hay Fever and Allergic Conjunctivitis, sponsored by Faes Farma, S.A.. Completed at 13 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2019-02-15.

Sponsored by Faes Farma, S.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
805
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 107 studies in Rhinitis, Allergic, Seasonal with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Rhinitis, Allergic, Seasonal · United States.

Enrollment
18th of 101
805 · median 446
Started
2007
with 11 others
Phase 2
20 of 107
none open now
Registered
28th of 107
by date

Among the 107 studies in Rhinitis, Allergic, Seasonal with a site in United States, this one is the 18th largest by enrollment of the 101 interventional ones that give a count, is one of 12 that started in 2007, is one of 20 in phase 2, and was the 28th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

1 of the 107 studies in Rhinitis, Allergic, Seasonal with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Rhinitis, Allergic, Seasonal with a site in United States, or all of them as a file.
02

Study summary

Evaluate the relative efficacy of four dosing regimens of bilastine tablets (given either once or twice per day) versus placebo in patients with Seasonal Allergic Rhinitis (SAR) in the Mountain Cedar season in south Texas and Oklahoma based on the mean change from baseline in Reflective Total Nasal Symptom Scores (TNSS) assessed over 14 days of treatment.

03

Conditions studied

  • Seasonal Allergic Rhinitis
  • Hay Fever
  • Allergic Conjunctivitis
  • Hypersensitivity

Keywords

  • Allergic Rhinitis
  • Mountain Cedar Pollen
  • Pollen Allergy
  • Rhinoconjunctivitis
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • clinical history of Seasonal Allergic Rhinoconjunctivitis with seasonal onset and offset of nasal allergy symptoms
  • documentation of a positive skin test within one year of screening to Mountain Cedar allergen

Exclusion criteria

Exclusion Criteria:

  • significant medical condition
  • significant nasal abnormality
  • significant cardiac condition
  • recent infection
  • use of other allergy medication during the study
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
805 participants (actual)

Study arms

  • Experimental
    1

    Bilastine 20mg once per day

    Drug: Bilastine

  • Experimental
    2

    Bilastine 20mg twice per day

    Drug: Bilastine

  • Experimental
    3

    Bilastine 10mg once per day

    Drug: Bilastine

  • Experimental
    4

    Bilastine 10mg twice per day

    Drug: Bilastine

  • Placebo comparator
    5

    Drug: Placebo

Interventions

  • Bilastine 10 or 20mg, once or twice daily for 14 days. Tablets

  • DrugPlacebo

    Placebo tablets twice daily for 14 days

06

What researchers measure

Primary outcomes

  1. Change in nasal symptom scores

    Time frame: 14 days

Secondary outcomes

  1. Change in ocular symptom scores and quality of life scores; standard safety assessments

    Time frame: 14 days

07

Study locations

13 sites
  • Oklahoma Allergy and Asthma Clinic
    Oklahoma City, Oklahoma 73104, United States
  • MetaClin Research Inc.
    Austin, Texas 78704, United States
  • Austin Clinical Research
    Austin, Texas 78750, United States
  • Lovelace Scientific Resources
    Austin, Texas 78759, United States
  • Kerrville Research Associates
    Kerrville, Texas 78028-6071, United States
  • Biogenics Research Institute
    San Antonio, Texas 78229, United States
  • DGD Research
    San Antonio, Texas 78229, United States
  • Diagnostics Research Group
    San Antonio, Texas 78229, United States
  • Southwest Allergy and Asthma Centre
    San Antonio, Texas 78229, United States
  • Sylvana Research Associates
    San Antonio, Texas 78229, United States
  • Live Oak Allergy and Asthma
    San Antonio, Texas 78233, United States
  • Allergy & Asthma Care of Waco
    Waco, Texas 76708, United States
  • Allergy Asthma Research Institute
    Waco, Texas 76712, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2007
First posted
Dec 17, 2007
Start
Dec 2007
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Last update
Feb 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00574379
Lead sponsor
Faes Farma, S.A.
Collaborators
Merck Sharp & Dohme LLC, Allied Research International
Responsible party
Sponsor
First posted
Dec 17, 2007
Start date
Dec 2007
Primary completion
Mar 2008
Completion
Mar 2008
Last update
Feb 15, 2019

Study contacts

Ander Sologuren, MD
study director · Faes Farma, S.A.
Paul Ratner, MD
principal investigator · Sylvana Research Associates

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bilastine

Start the discussion